First Liquid Biopsy for Neurologic Diseases
The link between metabolism and neurologic diseases
We have developed the first Research Use Only liquid biopsy test dedicated to neurologic diseases, using a simple blood draw to capture specific biomarkers that map each individual’s unique metabolic dysfunction. By decoding these molecular signatures, our platform is designed to reveal what is going wrong in a patient’s central nervous system, long before changes are visible on imaging or through symptoms alone. This deep metabolic insight empowers clinicians to move beyond one-size-fits-all care and design personalized treatment protocols.
Designed for easy adoption
Healthcare Providers:
Order our research use only test.
Simply collect a blood sample and send it to our lab.
Laboratories:
Process the sample with our Reagent.
Use our Web App to produce the test report.
One blood test, two components
FBB Reagent
Add the Reagent before RNA-sequencing library preparation to improve signal-to-noise.
FBB Web App
Use the Web App to let FBB's algorithms statistically determine neurologic health.
Use Cases
Metabolic Damage Identification
"Is the damage done to mitochondria, stem cells, or misfolded protein molecular machinery?"
Recovery Tracking
"To what extent is damage to metabolic pathways being addressed by treatment protocols over time?"
Workflow
The FBB Test runs on standard next-generation sequencers and does not require any new equipment.
As the FBB Test is for research use only and is neither a diagnostic nor cleared by the U.S. FDA, only licensed medical doctors are authorized to interpret the test's results.
